Note: in this setting, for this trial, no HRR mutation is required (like BRCA, ATM, ...). The treatment should basically (from my understanding) bomb the cancer with 225Ac (which is quite good on bone mets by the way) and then amplify the damage with olaparib to stop cancer cells to try to repair themselves.
This Phase 2 clinical trial is currently enrolling patients with metastatic castration-resistant prostate cancer (mCRPC).
This study is evaluating the combination of FPI-2265 (225Ac-PSMA-I&T), a targeted alpha therapy, and olaparib, a PARP inhibitor. The trial includes two parts: one for patients who previously received lutetium-177 therapy and another for those who did not.
The study will assess the efficacy, safety, and tolerability of this combination to determine the optimal dose and regimen. The goal is to improve outcomes for mCRPC patients with limited treatment options
